Literature DB >> 12486854

Hepatoma in a 40-year old male with hereditary hemochromatosis in the absence of cirrhosis. Implications of molecular diagnosis.

A Brage1, S Tomé, B Figueruela, I Abdulkader, J Martínez, E Varó.   

Abstract

Hepatocarcinoma is a poor-prognosis complication of hereditary hemochromatosis (HH). It occurs with a frequency rate of 10-20%. It is usually diagnosed during the 6th or 7th decade of life, and it appears almost exclusively in association with liver cirrhosis or in the presence of other known risk factors such as HBV or HCV. We present a case of hepatocarcinoma in a 40-year-old male with a long history of ethanol abuse of more than 100 g/day. The patient was studied through familial HH screening, and firstly diagnosed of HH on the base of biochemical blood tests. Subsequently, a C282Y mutation--homozygous--was identified. Studies performed on the patient did not suggest liver cirrhosis. Serology for HBV and HCV was negative. Concurrently, the patient presented an isolated liver lesion of 4 cm in segment 6 of the right lobe. Imaging techniques suggested an hepatoma. A surgical resection of the tumor by right hepatectomy was performed. The diagnosis of HH, complicated by hepatoma, on a non-cirrhotic liver was confirmed. After 2 years of post-surgery follow-up, a period during which the patient underwent treatment including periodic phlebotomies, he remains asymptomatic and with no signs of tumor recurrence.

Entities:  

Mesh:

Year:  2002        PMID: 12486854

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  2 in total

1.  Protective altruistic phlebotomy: hereditary haemochromatosis presenting as hepatocellular carcinoma in a non-cirrhotic 83-year-old man.

Authors:  Kohtaro Ooka; Ifeyinwa Onyiuke; Xuchen Zhang; Tamar Hamosh Taddei
Journal:  BMJ Case Rep       Date:  2016-09-02

Review 2.  Iron storage disease: facts, fiction and progress.

Authors:  Ernest Beutler
Journal:  Blood Cells Mol Dis       Date:  2007-05-31       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.